This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Athersys Reports Fourth Quarter And 2010 Annual Results

Stocks in this article: ATHX

CLEVELAND, March 14, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the fourth quarter of 2010 and for the year ended December 31, 2010.

Fourth Quarter and Recent Highlights Include:

  • Completed a registered direct offering in February 2011, generating net proceeds of $11.8 million through the issuance of common stock and warrants to purchase 0.3 of a share of common stock at an exercise price of $3.55 per share;
  • Enrolled first patient in the Phase II clinical study being conducted with Pfizer, administering MultiStem ® to patients suffering from ulcerative colitis;
  • Completed patient enrollment for the single dose arm of a clinical study administering MultiStem to patients being treated for leukemia or other blood-born cancers. The multiple ascending dose portion of this graft-versus-host disease, or GVHD, study is ongoing;
  • Published study in the January 2011 Journal of Neuroscience, conducted by the Case Western Reserve University School of Medicine and Athersys, showing the benefit of MultiStem therapy after spinal cord injury;
  • UTHealth and Athersys presented preclinical data illustrating multiple potential benefits of MultiStem for treating ischemic stroke;
  • Received three Therapeutic Discovery Project grants aggregating $733,000 as part of the Patient Protection and Affordable Care Act of 2010 related to MultiStem ® and our pharmaceutical development program in obesity and related metabolic conditions;
  • Recorded revenues of $3.3 million and a net loss of $2.1 million for the fourth quarter ended December 31, 2010; and
  • Ended the year with $15.2 million in cash, cash equivalents and available-for-sale securities, which does not reflect the impact of the recently completed financing.

"In the fourth quarter as throughout 2010, Athersys continued to achieve important milestones," said Gil Van Bokkelen, Ph.D., Chairman and Chief Executive Officer. "Three MultiStem programs are progressing in clinical studies, including a Phase II study in ulcerative colitis and Phase I studies in acute myocardial infarction and GVHD. We plan to advance our acute myocardial infarction and ischemic stroke programs into Phase II clinical trials in 2011. In addition, recently published results demonstrate the regenerative effects of MultiStem therapy after spinal cord injury, and these and other published results affirm our confidence in pursuing applications in stroke and other neurological conditions."

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs